we conclude that the present dose scheduling of acm is effective in the treatment of relapsing aml and that it should be introduced in combined chemotherapy in phase iii trials to compare its activity to that of daunorubicin or doxorubicin .
C0011015
daunorubicin
C0013089
doxorubicin